H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Genocea Biosciences (GNCA) today and set a price target of $5. The company’s shares closed on Friday at $0.68.
Pantginis observed:
“Valuation and risks to price target achievement. We reiterate our Buy rating and $5 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, GEN-009. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”
According to TipRanks.com, Pantginis is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -16.5% and a 27.6% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.
Genocea Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $3.50, which is a 414.7% upside from current levels. In a report issued on November 2, Cowen & Co. also maintained a Buy rating on the stock with a $2 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.39 and a one-year low of $0.49. Currently, Genocea Biosciences has an average volume of 371.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genocea Biosciences engages in the development and commercialization of cancer vaccines. It uses its proprietary technology platform ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses.
